CD274 and neoplasm: Hyperprogressive disease is a unique anti-PD-1/PD-L1–induced response pattern, characterized by accelerated tumor growth and shorter progression-free survival and overall survival.17 Therefore, it is a priority to identify patients with HPD before starting ICB treatment.